Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Orthopedics and Neurosurgery, Rothman Institute, Thomas Jefferson University, Philadelphia, PA, USA.
Neuromodulation. 2023 Aug;26(6):1171-1178. doi: 10.1016/j.neurom.2022.01.011. Epub 2022 Feb 25.
Spinal cord injury (SCI) treatment is still a challenge and new treatments that help these patients are being considered. Recent studies showed that the use of self-assembled peptide (SAP) can be useful in SCI treatment.
In this meta-analysis, we investigated the effect of SAP administration on locomotion recovery after SCI. Records were obtained from a comprehensive search of data bases. Articles were scrutinized for inclusion and exclusion criteria. Data were analyzed and results were reported as standardized mean difference (SMD) with 95% CI. Subgroup analysis was also performed.
A total of 14 studies and 17 separate experiments were included in the final analysis. Treatment with SAP structures after SCI resulted in a significant improvement in animal motor function (SMD = 1.13; 95% CI: 0.68-1.58; p < 0.0001). SAP treatment facilitated axon sprouting (SMD = 0.76; 95% CI: 0.33-1.18; p < 0.0001) and reduction of glial scar (SMD = -1.02; 95% CI: -1.94 to -0.09; p = 0.03). The difference in SAP type, its concentration, follow-up time, and SCI model had no effect on SAP effectiveness. In addition, SAP administration had a similar effect on improving locomotion in all three immediate, acute, and subacute phases which gives the good news of using this treatment for patients who are in the chronic phase.
SAP treatment can be considered as a potential treatment to help the motor recovery of SCI and axon regeneration.
脊髓损伤(SCI)的治疗仍然是一个挑战,人们正在考虑使用新的治疗方法来帮助这些患者。最近的研究表明,使用自组装肽(SAP)在 SCI 治疗中可能有用。
在这项荟萃分析中,我们研究了 SAP 给药对 SCI 后运动功能恢复的影响。通过全面搜索数据库获得记录。仔细检查文章以确定纳入和排除标准。对数据进行分析,并报告标准化均数差值(SMD)及其 95%置信区间(CI)。还进行了亚组分析。
共有 14 项研究和 17 个独立实验纳入最终分析。SCI 后 SAP 结构治疗可显著改善动物运动功能(SMD=1.13;95%CI:0.68-1.58;p<0.0001)。SAP 治疗促进轴突发芽(SMD=0.76;95%CI:0.33-1.18;p<0.0001)和减少神经胶质瘢痕(SMD=-1.02;95%CI:-1.94 至-0.09;p=0.03)。SAP 类型、浓度、随访时间和 SCI 模型的差异对 SAP 有效性没有影响。此外,SAP 给药对改善所有三个即时、急性和亚急性阶段的运动功能均具有相似的效果,这为慢性期患者使用这种治疗方法带来了好消息。
SAP 治疗可被视为一种潜在的治疗方法,有助于 SCI 运动功能恢复和轴突再生。